Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial
Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial is a paper indexed in ScholarIQ from OpenAlex.
How many citations does Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial have?
Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial has 1 citations in the OpenAlex counts ScholarIQ stores.
When was Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial published?
Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial has 2024 year in the ScholarIQ index.
What is the open-access status of Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial?
Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial has closed oa status in the ScholarIQ index.
What is the DOI of Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial?
The DOI for Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial is on the source record.
What is the OpenAlex record for Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial?
The OpenAlex for Efficacy and safety of apraglutide once-weekly in patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF): results from the stars study - a global phase 3 double-blind, randomized, placebo-controlled trial is on the source record.